BioBridge Global adds two industry leaders to Regenerative Medicine Advisory Board
06 mai 2019 09h00 HE
|
BioBridge Global
San Antonio, Texas, May 06, 2019 (GLOBE NEWSWIRE) -- BioBridge Global has added two new members to its Regenerative Medicine Advisory Board, a group composed of industry leaders with a wide range of...
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
01 févr. 2019 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and...
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
18 janv. 2019 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy...
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
17 janv. 2019 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related...
AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors
07 janv. 2019 07h06 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced the appointment of Philip J. Vickers, Ph.D.,...
AVROBIO, Inc. Added to NASDAQ Biotechnology Index
21 déc. 2018 10h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected...
AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR-RD-01 for the Treatment of Fabry Disease
19 déc. 2018 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 19, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare...
AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
18 déc. 2018 07h05 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the grant of non-qualified stock...
AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires
18 déc. 2018 07h00 HE
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced the appointment of four key senior...
AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
13 nov. 2018 08h00 HE
|
AVROBIO, Inc.
During the quarter, announced updated Fabry clinical data, acceptance of Clinical Trial Application for Gaucher, and continued platform optimization CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE...